The FDA approved the ADHD medication , a new selective norepinephrine reuptake inhibitor, for patients ages 6 to 17, Supernus Pharmaceuticals announced.
In other FDA news, Acadia Pharmaceuticals received a from the agency, which declined to approve pimavanserin (Nuplazid) for hallucinations and delusions associated with dementia-related psychosis due to a lack of statistical significance in certain subgroups of the phase III HARMONY study. The treatment was approved for hallucinations and delusions associated with Parkinson's disease psychosis in 2016.
Despite predictions that pandemic lockdowns would spur a spike in suicides, new CDC data found actually declined by 5.6% from 2019 to 2020, though deaths from overdose and alcohol both increased last year. (JAMA)
The FDA issued a safety update, warning about new data indicating a potential increased risk of arrhythmias in patients with pre-existing heart disease taking the bipolar disorder medication .
Adding the antidepressant further inhibited the production of COVID-19 particles in laboratory cells. (British Journal of Pharmacology)
People with ADHD were found to be at a higher risk for , including the need for hospitalization. (Journal of Attention Disorders)
Recognify Life Sciences now has a phase IIa study underway testing its investigational compound RL-007 for the treatment of .
No surprise here -- about two-thirds of men and one-third of women who had a and entered juvenile detention still struggled with their disorder up to 15 years later. (ScienceDaily)
![author['full_name']](https://clf1.medpagetoday.com/media/images/author/kristenMonaco_188.jpg)